3B Future Health Fund has participated in the cancer drug developer’s $5.8m extension round, investing alongside returning backers including M Ventures.
Switzerland-based oncology therapy developer iOnctura today secured a €5.1m ($5.8m) second series A tranche from 3B Future Health Fund, pharmaceutical firm Helsinn’s corporate venturing unit formerly called Helsinn Investment Fund.
Pharmaceutical firm Merck Group’s investment unit M Ventures also participated in the extension, as did fellow existing backers Inkef Capital, Schroder Adveq and VI Partners, which lifted the series A funding to $24.5m.
Merck founded iOnctura in 2017 and provided an undisclosed amount of seed funding through M Ventures (then…
